Fresenius SE & Co. KGaA, DE0005785604

Fresenius stock heads into the open after a 44.68 euro close

Published on 09/10/2026 at 08:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At the close on September 8, 2026, Fresenius stock ended at 44.68 euros on Xetra, down 0.6 percent. UBS kept a Buy rating with a 56.00 euro target, and the share price sat between a one-year low of 35.11 euros and a one-year high of 52.96 euros.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht
Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fresenius stock closed at 44.68 euros on Xetra on September 8, 2026, down 0.6 percent. The move left Fresenius SE & Co. KGaA (ISIN DE0005785604) below UBS's 56.00 euro target and between a one-year low of 35.11 euros and a one-year high of 52.96 euros.

September 8, 2026 close

As ad hoc news reported, UBS kept a Buy rating and a 56.00 euro price target on the shares, while the average analyst target stood at 55.28 euros. That leaves the Xetra close 11.32 euros, or 20.2 percent, below the UBS target.

Price data cited in the same report put the Xetra close at 44.68 euros, with the stock still above the 35.11 euro one-year low and below the 52.96 euro one-year high. The gap to the recent peak was 8.28 euros, or 15.6 percent.

Today ahead of the open

As ad hoc news noted, Fresenius has an extraordinary general meeting listed for September 3, 2026 in the same calendar overview. The same source also lists a dividend detachment of 0.20 US dollars per share on September 1, 2026, which remains part of the recent market backdrop.

Disclaimer...

en | DE0005785604 | FRESENIUS SE & CO. KGAA | boerse | 70079823 | bgmi